Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway

BMC Cancer

Yue-Zu Fan³  Xing-Sui Lu³  Ze-Ming Zhao³  Zhong-Yan Liu³  Chun-Yan Ge¹  Wen-Zhong Zhang²  Wei Sun⁴  Jing-Tao Zhang³ 

[1]Department of Oncology, Shanghai Yangpu Geriatric Hospital, Shanghai 200090, P.R. China

[2]Department of Surgery, Shanghai Pudong New Area People’s Hospital, Shanghai 201299, P.R. China

[3]Department of Surgery, Tongji Hospital, Tongji University School of Medicine, Tongji University, Shanghai 200065, P.R. China

[4]Department of Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Tongji University, Shanghai 200072, P.R. China

关键词: Signaling pathway;    Xenograft model;    3-dimensional matrix;    Vasculogenic mimicry;    Norcantharidin;    Gallbladder neoplasm;   

Others  :  858963
DOI  :  10.1186/1471-2407-14-193

 received in 2013-10-09, accepted in 2014-03-10,  发布年份 2014

【 摘 要 】

Background

Vasculogenic mimicry (VM) is a novel tumor blood supply in some highly aggressive malignant tumors. Recently, we reported VM existed in gallbladder carcinomas (GBCs) and the formation of the special passage through the activation of the PI3K/MMPs/Ln-5γ2 signaling pathway. GBC is a highly aggressive malignant tumor with disappointing treatments and a poor prognosis. Norcantharidin (NCTD) has shown to have multiple antitumor activities against GBCs, etc; however the exact mechanism is not thoroughly elucidated. In this study, we firstly investigated the anti-VM activity of NCTD as a VM inhibitor for GBCs and its underlying mechanisms.

Methods

In vitro and in vivo experiments to determine the effects of NCTD on proliferation, invasion, migration, VM formation, hemodynamic and tumor growth of GBC-SD cells and xenografts were respectively done by proliferation, invasion, migration assays, H&E staining and CD31-PAS double stainings, optic/electron microscopy, tumor assay, and dynamic micro-MRA. Further, immunohistochemistry, immunofluorescence, Western blotting and RT-PCR were respectively used to examine expression of VM signaling-related markers PI3-K, MMP-2, MT1-MMP and Ln-5γ2 in GBC-SD cells and xenografts in vitro and in vivo.

Results

After treatment with NCTD, proliferation, invasion, migration of GBC-SD cells were inhibited; GBC-SD cells and xenografts were unable to form VM-like structures; tumor center-VM region of the xenografts exhibited a decreased signal in intensity; then cell or xenograft growth was inhibited. Whereas all of untreated GBC-SD cells and xenografts formed VM-like structures with the same conditions; the xenograft center-VM region exhibited a gradually increased signal; and facilitated cell or xenograft growth. Furthermore, expression of MMP-2 and MT1-MMP products from sections/supernates of 3-D matrices and the xenografts, and expression of PI3-K, MMP-2, MM1-MMP and Ln-5γ2 proteins/mRNAs of the xenografts were all decreased in NCTD or TIMP-2 group; (all P < 0.01, vs. control group); NCTD down-regulated expression of these VM signaling-related markers in vitro and in vivo.

Conclusions

NCTD inhibited tumor growth and VM of human GBCs in vitro and in vivo by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway. It is firstly concluded that NCTD may be a potential anti-VM agent for human GBCs.

【 授权许可】

   
2014 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS: Gallbladder cancer. Am J Surg 2008, 196:252-264.
• [2]Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, Alonso de Ruiz P, Aristi Urista G, Nervi F: Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001, 51:349-364.
• [3]Reddy SK, Clary BM: Surgical management of gallbladder cancer. Surg Oncol Clin N Am 2009, 18:307-324.
• [4]Li LD, Zhang SW, Lu FZ, Mu R, Sun XD, Huangpu XM: Research on characteristics of mortality spectrum and type composition of malignant tumors in China. Zhonghua Zhongliu Zazhi 1997, 19:323-328.
• [5]Hsing AW, Gao YT, Devesa SS, Jin F, Fraumeni JF Jr: Rising incidence of biliary tract cancers in Shanghai, China. Int J Cancer 1998, 75:368-370.
• [6]Chakravarty KD, Yeh CN, Jan YY, Chen MF: Factors influencing long-term survival in patients with T3 gallbladder adenocarcinoma. Digestion 2009, 79:151-157.
• [7]Konstantinidis IT, Deshpande V, Genevay M, Berger D, Fernandez-del Castillo C, Tanabe KK, Zheng H, Lauwers GY, Ferrone CR: Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience. Arch Surg 2009, 144:441-447.
• [8]Ishii H, Furuse J, Yonemoto N, Nagase M, Yoshino M, Sato T: Chemotherapy in the treatment of advanced gallbladder cancer. Oncology 2004, 66:138-142.
• [9]Morise Z, Sugioka A, Tanahashi Y, Okabe Y, Ikeda M, Kagawa T, Takeura C: Treatment of patients with unresectable advanced carcinoma of biliary tract chemotherapy and surgical resection. Anticancer Res 2009, 29:1783-1786.
• [10]Mahantshetty UM, Palled SR, Engineer R, Homkar G, Shrivastava SK, Shukla PJ: Adjuvant radiation therapy in gallbladder cancers: 10 years experience at Tata Memorial Hospital. J Cancer Res Ther 2006, 2:52-56.
• [11]Mojica P, Smith D, Ellenhorn J: Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol 2007, 96:8-13.
• [12]Shukla PJ, Barreto SG: Gallbladder cancer: we need to do better! Ann Surg Oncol 2009, 16:2084-2085.
• [13]McNamara MG, Metran-Nascente C, Knox JJ: State-of-the-art in the management of locally advanced and metastatic gallbladder cancer. Curr Opin Oncol 2013, 25:425-431.
• [14]Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, Trent JM, Meltzer PS, Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999, 155:739-752.
• [15]Warso MA, Maniotis AJ, Chen X, Majumdar D, Patel MK, Shilkaitis A, Gupta TK, Folberg R: Prognostic significance of periodic acid-Schiff-positive patterns in primary cutaneous melanoma. Clin Cancer Res 2001, 7:473-477.
• [16]Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, Konishi F: Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 2002, 99:821-828.
• [17]Sun B, Zhang S, Zhang D, Du J, Guo H, Zhao X, Zhang W, Hao X: Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 2006, 16:693-698.
• [18]Li M, Gu Y, Zhang Z, Zhang S, Zhang D, Saleem AF, Zhao X, Sun B: Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res 2010, 16:259-266.
• [19]Baeten CI, Hillen F, Pauwels P, de Bruine AP, Baeten CG: Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum 2009, 52:2028-2035.
• [20]Fan YZ, Sun W, Zhang WZ, Ge CY: Vasculogenic mimicry in human primary gallbladder carcinoma and clinical significance thereof. Zhonghua Yi Xue Za Zhi 2007, 87:145-149.
• [21]Sun W, Shen ZY, Zhang H, Fan YZ, Zhang WZ, Zhang JT, Lu XS, Ye C: Overexpression of HIF-1α in primary gallbladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis. Oncol Rep 2012, 27:1990-2002.
• [22]Sun W, Fan YZ, Zhang WZ, Ge CY: A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro. J Exp Clin Cancer Res 2011, 30:46. BioMed Central Full Text
• [23]Fan YZ, Sun W: Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg 2010, 2:117-127.
• [24]Lu XS, Sun W, Ge CY, Zhang WZ, Fan YZ: Contribution of the PI3-K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas. Int J Oncol 2013, 42:2103-2115.
• [25]van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW, Hendrix MJ: Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 2004, 96:1473-1477.
• [26]Wang GS: Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol 1989, 26:147-162.
• [27]Liu J, Gao J, Liu X: Advances in the study of Cantharidin and its derivatives. Zhong Yao Cai 2003, 26:453-455.
• [28]Ho YP, To KK, Au-Yeung SC, Wang X, Lin G, Han X: Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety. J Med Chem 2001, 44:2065-2068.
• [29]Yang EB, Tang WY, Zhang K, Cheng LY, Mack PO: Norcantharidin inhibits growth of human HepG2 cell-transplanted tumor in nude mice and prolongs host survival. Cancer Lett 1997, 117:93-98.
• [30]Yi SN, Wass J, Vincent P, Iland H: Inhibitory effect of norcantharidin on K562 human myeloid leukemia cells in vitro. Leuk Res 1991, 15:883-886.
• [31]An WW, Wang MW, Tashiro S, Onodera S, Ikejima T: Norcantharidin induces human melanoma A375-S2 cell apoptosis through mitochondrial and caspase pathways. J Korean Med Sci 2004, 19:560-566.
• [32]Fan YZ, Fu JY, Zhao ZM, Chen CQ: Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro. Hepatobiliary Pancreat Dis Int 2007, 6:72-80.
• [33]Fan YZ, Zhao ZM, Fu JY, Chen CQ, Sun W: Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo. Hepatobiliary Pancreat Dis Int 2010, 9:414-422.
• [34]Zhang JT, Fan YZ, Chen CQ, Zhao ZM, Sun W: Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo. Int J Oncol 2012, 40:1501-1514.
• [35]Tian F, Zhang XW, Tong YG, Yi YH, Zhang SL, Li L, Sun P, Lin LP, Ding J: PE, a new sulfated saponin from sea cucumber, exhibits anti-angiogenic and anti-tumor activities in vitro and in vivo. Cancer Biol Ther 2005, 4:874-882.
• [36]Zhou YX, Huang YL: Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study. Chin Med J (Engl) 2009, 122:1666-1673.
• [37]Zhang S, Li M, Gu Y, Liu Z, Xu S, Cui Y, Sun B: Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J Exp Clin Cancer Res 2008, 27:1-9. BioMed Central Full Text
• [38]Cong R, Sun Q, Yang L, Gu H, Zeng Y, Wang B: Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells. J Exp Clin Cancer Res 2009, 28:124. BioMed Central Full Text
• [39]Fu D, He X, Yang S, Xu W, Lin T, Feng X: Zoledronic acid inhibits vasculogenic mimicry in murine osteosarcoma cell line in vitro. BMC Musculoskelet Disord 2011, 12:146. BioMed Central Full Text
• [40]Chen LX, He YJ, Zhao SZ, Wu JG, Wang JT, Zhu LM, Lin TT, Sun BC, Li XR: Inhibition of tumor growth and vasculogenic mimicry by curcumin through down-regulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model. Cancer Biol Ther 2011, 11:229-235.
• [41]Jenab-Wolcott J, Giantonio BJ: Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther 2009, 9:507-517.
• [42]Hu B, Cheng SY: Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep 2009, 11:111-166.
• [43]Folkman J: Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 2006, 312:594-607.
• [44]Lawler J: Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002, 6:1-12.
• [45]Grothey A, Galanis E: Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009, 6:507-518.
• [46]Gille J: Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol 2006, 15:175-186.
• [47]Chen HX, Cleck JN: Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009, 6:465-477.
• [48]Higa GM, Abraham J: Biological mechanisms of Bevacizumab-associated adverse events. Expert Rev Anticancer Ther 2009, 9:999-1007.
• [49]Hess AR, Seftor EA, Seftor RE, Hendrix MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 2003, 63:4757-4762.
• [50]Seftor RE, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V, Hendrix MJ: Cooperative interactions of laminin 5 gamma 2 chain, matrix metalloproteinase-2, and membrane type-1- matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001, 61:6322-6327.
• [51]Seftor RE, Seftor EA, Kirschmann DA, Hendrix MJ: Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther 2002, 1:1173-1179.
• [52]Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM, Hendrix MJ: Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol 2004, 190:899-909.
• [53]Link W, Rosado A, Fominaya J, Thomas JE, Carnero A: Membrane localization of all class I PI3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. J Cell Biochem 2005, 95:979-989.
• [54]McCawley LJ, Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000, 6:149-156.
• [55]Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999, 103:1237-1241.
• [56]Seiki M: Membrane-type matrix metalloproteinases. Apmis 1999, 107:137-143.
• [57]Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG: Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991, 83:775-779.